BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//BioCatalystFeed//bcf//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BioCatalystFeed IBO catalysts
X-WR-CALDESC:Scheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:166a783561b6ef6d35b3@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:IBO P1/P2 readout (est.): Study to Evaluate IMP9064 as a Monotherap
 y or in Combination in Patients With Advanced Solid Tumors
DESCRIPTION:Study to Evaluate IMP9064 as a Monotherapy or in Combination in
  Patients With Advanced Solid Tumors\nNCT05269316 | PHASE1/PHASE2 | RECRUI
 TING | sponsor: Impact Therapeutics\, Inc.\nPrimary completion date (ESTIM
 ATED)\; top-line results usually follow later.\nTicker IBO (confidence 0.6
 )\nSource: https://clinicaltrials.gov/study/NCT05269316\nScheduling/refere
 nce data from public records\; dates can move. Not investment\, legal or m
 edical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05269316
CATEGORIES:readout,ESTIMATED
END:VEVENT
END:VCALENDAR
